Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to orphan drug tax credit; Issues related to rare disease; Issues related to the Inflation Reduction Act of 2022 (PL 117-169); Issues related to orphan drugs under the Drug Price Negotiation Program.
2025 · 4th Quarter (Oct 1 - Dec 31)
ALEXION PHARMACEUTICALS, INC.
Filed by FORBES-TATE.
Open official filingSource-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 18, 2026
- Income
- $50,000.00
- Expenses
- Not reported
- Registrant
- FORBES-TATE
- Filing UUID
- e87e691b-d6f1-4c74-b6c2-69105a1d7456
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to healthcare, including drug pricing and Medicare Part D; Issues related to the Inflation Reduction Act of 2022 (PL 117-169).
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.